Important Information for Investors: Class Action Lawsuit Filed Against ESSA Pharma Inc.
NEW YORK, Feb. 18, 2025 – Levi & Korsinsky, LLP announces that a class action securities lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased ESSA Pharma Inc. (“ESSA Pharma” or the “Company”) (NASDAQ: EPIX) common stock between February 24, 2021, and December 15, 2021. The complaint alleges that the Company issued materially false and misleading statements and failed to disclose material information.
Allegations in the Lawsuit
The complaint alleges that ESSA Pharma made false and misleading statements and failed to disclose that:
- The Company’s clinical trial results for its lead compound, EPI-5895, were not as promising as represented;
- The Company’s clinical trial data was manipulated;
- The Company’s financial statements were misstated;
- The Company lacked effective internal controls over financial reporting;
Impact on Individual Investors
If you invested in ESSA Pharma between February 24, 2021, and December 15, 2021, you may be entitled to recover your losses. Investors who wish to learn more about the case and how they can participate should contact Levi & Korsinsky, LLP by email at [email protected] or call 212-363-7500. The deadline to apply for lead plaintiff status is May 2, 2025.
Impact on the World
The class action lawsuit against ESSA Pharma is a significant development in the biotech industry, as it highlights the importance of transparency and accuracy in clinical trial data and financial reporting. The lawsuit also underscores the need for investors to carefully research companies before investing and to be vigilant for any potential red flags.
Conclusion
Levi & Korsinsky, LLP encourages investors in ESSA Pharma to monitor the case closely and to contact the firm if they have any questions or concerns. The lawsuit serves as a reminder that investors must be diligent in their research and that companies must provide accurate information to the investing public. As the case progresses, further information will be provided.
If you invested in ESSA Pharma between February 24, 2021, and December 15, 2021, please contact Levi & Korsinsky, LLP to discuss your potential recovery options.
Levi & Korsinsky, LLP
30 Broad Street – 24th Floor
New York, NY 10004
Email: [email protected]
Phone: 212-363-7500
Toll-Free: 877-363-5972
Fax: 212-363-7171
For more information, please visit:
https://www.zlk.com/pslra-1/essa-pharma-inc-loss-submission-form?wire=3
Levi & Korsinsky, LLP is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, accounting fraud, and consumer protection violations. For more information, please visit:
https://www.levikorsinsky.com/
ATTORNEY ADVERTISING. SEC REG. G GENERAL. THIS ADVERTISMENT IS NOT A SOLICITATION FOR INVESTORS. THE FOLLOWING INFORMATION APPLIES ONLY TO INVESTORS WHO PURCHASED THE SECURITIES DISCUSSED HEREIN BETWEEN THE CLASS PERIOD START DATE AND THE CLASS PERIOD END DATE INDICATED, IN THE PARTICULAR SECURITIES DISCUSSED HEREIN.
Levi & Korsinsky, LLP is not registered or licensed by any regulatory body in any jurisdiction. We are not attorneys licensed to practice law in any jurisdiction. We seek to act as a “settlement fund” for the benefit of our class members in shareholder class actions. Our goal is to provide investor class members with the best possible recovery in securities class actions.
This press release may be considered attorney advertising in some jurisdictions under the applicable law and ethical rules. Any class member in this case may retain counsel of their choice.
